公开(公告)号：US20200022960A1

公开(公告)日：2020-01-23

申请号：US16477416

申请日：2018-01-11

Applicant: Kowa Company, Ltd.

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61P1/16

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US20220054459A1

公开(公告)日：2022-02-24

申请号：US17515945

申请日：2021-11-01

Applicant: Kowa Company, Ltd.

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61P1/16

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US12042483B2

公开(公告)日：2024-07-23

申请号：US17515945

申请日：2021-11-01

Applicant: Kowa Company, Ltd.

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61P1/16 ,  A61K31/7034 ,  A61K31/7048

CPC classification number: A61K31/423 ,  A61P1/16 ,  A61K31/7034 ,  A61K31/7048

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US20240325356A1

公开(公告)日：2024-10-03

申请号：US18741528

申请日：2024-06-12

Applicant: Kowa Company, Ltd

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61K31/7034 ,  A61K31/7048 ,  A61P1/16

CPC classification number: A61K31/423 ,  A61P1/16 ,  A61K31/7034 ,  A61K31/7048

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) a agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.